

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1 Name and Address of Company

HAVN Life Sciences Inc. (the “Company”)
Suite 2200, 885 Wet Georgia Street
Vancouver, BC V6C 3E8

Item 2 Date of Material Change

July 2, 2021

Item 3 News Release

A news release with respect to the contents of this report was issued on July 2, 2021 and was disseminated through the facilities of recognized newswire services. A copy of the news release was filed on SEDAR.

Item 4 Summary of Material Change

The Company announced the appointment of a new Chief Financial Officer.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

The Company announced that Mr. Gordon Clissold has joined the Company as Chief Financial Officer.

Mr. Clissold is a Chartered Professional Accountant who has been recognized for his contributions to the accounting profession. He has over 20 years of experience as an operational and financial manager, in both public and private companies, with career experience spanning technology, manufacturing, wholesale distribution, and professional services. His management competencies encompass organizational leadership, strategic planning, corporate finance, financial modelling, ERP and financial systems implementation, internal control development, and due diligence for mergers and acquisitions. Mr. Clissold has led the international expansion of companies and has established a reputation for being able to identify the talent necessary to build high-performing teams.

The Company further announces that Eli Dusenbury will remain on as a consultant providing accounting services on an as needed-basis.

Please see the news release attached hereto for a full description of the material change.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The name and business number of the executive officers of the Company who are knowledgeable of the material change and this report are:

Tim Moore
Chief Executive Officer
Telephone – 604-359-0060

Item 9 Date of Report

July 2, 2021



Havn Life Announces Management Change

July 2, 2021

Vancouver, BC - Havn Life Sciences Inc. (CSE: [HAVN](#)) (OTC: [HAVLF](#)) (FSE: [5NP](#)) (the “Company” or “Havn Life”) announces that Mr. Gordon Clissold has joined the Company as Chief Financial Officer.

Mr. Clissold is a Chartered Professional Accountant who has been recognized for his contributions to the accounting profession. He has over 20 years of experience as an operational and financial manager, in both public and private companies, with career experience spanning technology, manufacturing, wholesale distribution, and professional services. His management competencies encompass organizational leadership, strategic planning, corporate finance, financial modelling, ERP and financial systems implementation, internal control development, and due diligence for mergers and acquisitions. Mr. Clissold has led the international expansion of companies and has established a reputation for being able to identify the talent necessary to build high-performing teams.

The Company further announces that Eli Dusenbury will remain on as a consultant providing accounting services on an as needed-basis.

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on [Facebook](#), [Twitter](#), [Instagram](#) and [Youtube](#).

Contact:

Investor Relations: ir@havnlife.com 604 687 7130
Media: savi@emergence-creative.com 647 896-8078

The CSE has not reviewed, approved or disapproved the content of this press release

